Advertisement
Advertisement
U.S. markets close in 2 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Gemini Therapeutics, Inc. (GMTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6600+0.0200 (+1.22%)
As of 03:41PM EDT. Market open.
Advertisement

Gemini Therapeutics, Inc.

300 One Kendall Square
3rd Floor
Cambridge, MA 02139
United States
617 401 4400
https://www.geminitherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. Georges Gemayel C.F.A., Ph.D.Interim Pres & CEO and Exec. Chairperson256.73kN/A1960
Mr. Brian PiekosChief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer549.73kN/A1976
Mr. Jason Patrick Meyenburg M.B.A., M.D.Advisor715.96kN/A1978
Mr. Patrick TruesdellVP of Fin. & ControllerN/AN/A1981
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Gemini Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement